Genetic Landscape of Multistep Hepatocarcinogenesis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Feb 15

PMID 35158835

Authors

Haruhiko Takeda

Atsushi Takai

Yuji Eso

Ken Takahashi

Hiroyuki Marusawa

Hiroshi Seno

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Although several targeted therapy agents are available for advanced HCC, their antitumor efficacy remains limited. As the complex genetic landscape of HCC would compromise the antitumor efficacy of targeted therapy, a deeper understanding of the genetic landscape of hepatocarcinogenesis is necessary. Recent comprehensive genetic analyses have revealed the driver genes of HCC, which accumulate during the multistage process of hepatocarcinogenesis, facilitating HCC genetic heterogeneity. In addition, as early genetic changes may represent key therapeutic targets, the genetic landscapes of early HCC and precancerous liver tissues have been characterized in recent years, in parallel with the advancement of next-generation sequencing analysis. In this review article, we first summarize the landscape of the liver cancer genome and its intratumor heterogeneity. We then introduce recent insight on early genetic alterations in hepatocarcinogenesis, especially those in early HCC and noncancerous liver tissues. Finally, we summarize the multistep accumulation of genetic aberrations throughout cancer progression and discuss the future perspective towards the clinical application of this genetic information.

Citing Articles

Mint3 as a Molecular Target Activated in the Early Stage of Hepatocarcinogenesis.

Nishitani M, Okada H, Nio K, Hayashi T, Terashima T, Iida N Int J Mol Sci. 2025; 26(4).

PMID: 40003897 PMC: 11855386. DOI: 10.3390/ijms26041430.

Multi-omics Insights into PDHA1 as a Predictive Biomarker for Prognosis, Immunotherapy Efficacy, and Drug Sensitivity in Hepatocellular Carcinoma.

Pan Y, Zhang Y, Mao D, Fang Z, Ma Y, Jin D ACS Omega. 2024; 9(46):46492-46504.

PMID: 39583658 PMC: 11579764. DOI: 10.1021/acsomega.4c08010.

Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma.

Ye J, Lin Y, Liao Z, Gao X, Lu C, Lu L NPJ Precis Oncol. 2024; 8(1):262.

PMID: 39548284 PMC: 11568154. DOI: 10.1038/s41698-024-00752-1.

Advanced Imaging of Hepatocellular Carcinoma: A Review of Current and Novel Techniques.

Nguyen T, Vennatt J, Downs L, Surabhi V, Stanietzky N J Gastrointest Cancer. 2024; 55(4):1469-1484.

PMID: 39158837 DOI: 10.1007/s12029-024-01094-8.

Interplay Between Fatty Acids, Stearoyl-Co-A Desaturase, Mechanistic Target of Rapamycin, and Yes-Associated Protein/Transcriptional Coactivator With PDZ-Binding Motif in Promoting Hepatocellular Carcinoma.

Benhammou J, Sinnett-Smith J, Pisegna J, Rozengurt E Gastro Hep Adv. 2024; 2(2):232-241.

PMID: 39132609 PMC: 11308718. DOI: 10.1016/j.gastha.2022.07.017.

References

El-Serag H . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264-1273.e1. PMC: 3338949. DOI: 10.1053/j.gastro.2011.12.061. View

Hoshida Y, Nijman S, Kobayashi M, Chan J, Brunet J, Chiang D . Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69(18):7385-92. PMC: 3549578. DOI: 10.1158/0008-5472.CAN-09-1089. View

Sung W, Zheng H, Li S, Chen R, Liu X, Li Y . Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012; 44(7):765-9. DOI: 10.1038/ng.2295. View

Kudo M . Biomarkers and Personalized Sorafenib Therapy. Liver Cancer. 2015; 3(3-4):399-404. PMC: 4531426. DOI: 10.1159/000343870. View

Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T . AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24(3):245-50. DOI: 10.1038/73448. View

Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, Kojima F . Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol. 2016; 66(2):363-373. DOI: 10.1016/j.jhep.2016.09.021. View

Nault J, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G . Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015; 47(10):1187-93. DOI: 10.1038/ng.3389. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

10.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

11.

Desert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S . Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology. 2017; 66(5):1502-1518. DOI: 10.1002/hep.29254. View

12.

Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K . Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015; 6:6120. DOI: 10.1038/ncomms7120. View

13.

Midorikawa Y, Yamamoto S, Tatsuno K, Renard-Guillet C, Tsuji S, Hayashi A . Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression. Cancer Res. 2020; 80(18):3810-3819. DOI: 10.1158/0008-5472.CAN-20-0225. View

14.

Hussain S, Schwank J, Staib F, Wang X, Harris C . TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007; 26(15):2166-76. DOI: 10.1038/sj.onc.1210279. View

15.

Kumar A, Coleman I, Morrissey C, Zhang X, True L, Gulati R . Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016; 22(4):369-78. PMC: 5045679. DOI: 10.1038/nm.4053. View

16.

Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco M, Matsui K . Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget. 2016; 7(31):49091-49098. PMC: 5226492. DOI: 10.18632/oncotarget.10077. View

17.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

18.

Shibata T, Aburatani H . Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014; 11(6):340-9. DOI: 10.1038/nrgastro.2014.6. View

19.

Hou Y, Guo H, Cao C, Li X, Hu B, Zhu P . Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas. Cell Res. 2016; 26(3):304-19. PMC: 4783472. DOI: 10.1038/cr.2016.23. View

20.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View